Click on image to view larger version.
Figure 1 Kaplan-Meier survival estimates in 178 patients with primary pulmonary hypertension (PPH) from the initiation of epoprostenol (PGI2) therapy. For comparison, survival data are also shown for a historical control group of 135 patients with PPH matched for New York Heart Association functional class and who never received intravenous (IV) epoprostenol therapy. In the group of patients treated with PGI2 (solid line), the overall survival rates at one, two, three, and five years were 85%, 70%, 63%, and 55%, respectively, as compared with 58%, 43%, 33%, and 28% in the historical control group (dashed line) (p < 0.0001 by the Cox-Mantel log-rank test).